Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine(2016)10.1056/nejmoa1606774Source: DataRank Database

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer is a research paper published in New England Journal of Medicine (2016). On theSindex it has a DataRank of 1.4. It has been cited 9,979 times.

N/A

1.4DataRank · unranked

Scored on demand from live citation data

Open Access9,979 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 441.00)OA: bronzeTopics (46)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

1.4

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (21)

Delvys Rodríguez-Abreu,Andrew G. Robinson,Rina Hui ORCID,Tibor Csőszi ORCID,Andrea Fülöp

Live enrichment

PubMed:27718847 OpenAlex:https://openalex.org/W2527905628

FWCI

441.00

Citation Percentile

1.0%

Citation Trend

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

bronze

journalhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774?articleTools=true

publisherhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774?articleTools=true

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774

journalhttps://doi.org/10.1056/nejmoa1606774

repositoryhttps://pubmed.ncbi.nlm.nih.gov/27718847

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentPeptidase Inhibition and AnalysisAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansIntention to Treat AnalysisLung NeoplasmsMaleMiddle AgedPlatinum CompoundsProgrammed Cell Death 1 ReceptorSurvival Analysis

MeSH Terms

AdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedSurvival AnalysisPlatinum CompoundsIntention to Treat AnalysisProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, Humanized

Keywords

PembrolizumabMedicineLung cancerInternal medicineHazard ratioOncologyChemotherapyCancerGastroenterologyConfidence intervalImmunotherapy

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

10.6084/m9.figshare.26701780.v1figshare

Additional file 1 of CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

10.6084/m9.figshare.26701780figshare

Additional file 2 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

10.6084/m9.figshare.14361534.v1figshare

10.6084/m9.figshare.14361534figshare

Additional file 1 of Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

10.6084/m9.figshare.12082338.v1figshare

Additional file 1 of Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

10.6084/m9.figshare.12082338figshare

Additional file 1 of Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

10.6084/m9.figshare.12177813figshare

Additional file 1 of Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

10.6084/m9.figshare.12177813.v1figshare

Additional file 1 of Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections

10.6084/m9.figshare.12364982.v1figshare

Additional file 1 of Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections

10.6084/m9.figshare.12364982figshare

Additional file 1 of Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

10.6084/m9.figshare.12940321.v1figshare

10.6084/m9.figshare.12940321figshare

Additional file 1 of Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer

10.6084/m9.figshare.13100761.v1figshare

Additional file 1 of Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer

10.6084/m9.figshare.13100761figshare

Additional file 1 of Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

10.6084/m9.figshare.13279790.v1figshare

Additional file 1 of Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

10.6084/m9.figshare.13279790figshare

Additional file 2 of Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

10.6084/m9.figshare.13279793.v1figshare